Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM

New drugs are needed for the treatment of relapsed acute lymphoblastic leukemia and preclinical evaluation of the MEK inhibitor, selumetinib, has shown that this drug has excellent activity in those leukemias with RAS pathway mutations. The proapoptotic protein, BIM is pivotal in the induction of ce...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Haematologica
Hoofdauteurs: Matheson, Elizabeth C., Thomas, Huw, Case, Marian, Blair, Helen, Jackson, Rosanna K., Masic, Dino, Veal, Gareth, Halsey, Chris, Newell, David R., Vormoor, Josef, Irving, Julie A.E.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Ferrata Storti Foundation 2019
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6717586/
https://ncbi.nlm.nih.gov/pubmed/30655370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.185975
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items